Coherus BioSciences (NASDAQ:CHRS) announced that the United States Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) resubmission for Toripalimab in combination with Gemcitabine and Cisplatin as first-line treatment for patients with advanced recurrent or metastatic nasopharyngeal carcinoma (NPC)
The regulatory agency has set Prescription Drug User Fee Act (PDUFA) action date for December 23, 2022.
